Acthar is a highly purified, proprietary, prolonged-release formulation of naturally occurring adrenocorticotropic hormone (ACTH) and other peptides.1

Acthar has been approved by the FDA for multiple conditions since 1952 and for IS since 2010.10

In clinical trials, Acthar satisfied the American Academy of Neurology (AAN) and Child Neurology Society (CNS) guidelines on treating IS.2,5,11-13

Acthar is contraindicated in patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction, or sensitivity to proteins of porcine origins.

Appropriate patients for Acthar

Under 2 years of age with any etiology of IS1-3:

  • Cryptogenic
  • Symptomatic, including tuberous sclerosis (TS)

Characterized by2:

  • Confirmed clusters of myoclonic or tonic seizures (spasms)
  • Hypsarrhythmia confirmed by EEG

Acthar should never be administered intravenously. Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of Acthar.

Helpful Resources

Step-by-Step Injection Training Guide

Download this convenient and easy-to-follow Injection Training Guide for caregivers of children with IS.

Physician Referral/Prescription Form

Download for your practice to complete.

Take the guesswork out of dosing Acthar for IS

From per-injection volume to number of vials, our calculator simplifies the process.